

2024

Cumulative Antimicrobial Susceptibility Report



INPATIENT DATA

PeaceHealth St. John Medical Center

January 1 – December 31, 2024

Dash (-) = not tested, inappropriate, or < 30 strains tested. R = intrinsically resistant.

GRAM NEGATIVE ORGANISM	PERCENT SUSCEPTIBLE	# Isolates Tested	Beta-lactams												Fluoro-quinolones	Aminoglycosides	Miscellaneous				
			Penicillins			Cephems			Carbapenems												
			Ampicillin	Amoxicillin/clavulanic acid	Piperacillin/tazobactam	Cefazolin	Ceftazidime	Ceftriaxone	Cefepime	Cefotaxin	Cefpodoxime	Ertapenem	Meropenem	Ciprofloxacin	Levofloxacin	Amikacin	Gentamicin	Tobramycin			
<i>Enterobacter cloacae</i> complex	56	56	R	R	-	R	-	-	95	R	-	93	99	95	95	100	100	100	39	96	93
<i>Escherichia coli</i>	979	63	90	98	90	97	94	98	95	91	100	100	83	79	100	95	95	98	82	84	
<i>Klebsiella oxytoca</i>	46	R	93	91	-	-	93	100	98	-	100	100	96	98	-	98	98	-	95	96	
<i>Klebsiella pneumoniae</i>	153	R	96	97	96	98	95	99	97	95	100	100	94	92	100	99	97	26	90	92	
<i>Proteus mirabilis</i>	70	83	100	100	100	100	100	100	94	100	100	83	83	100	96	97	R	R	83		
<i>Pseudomonas aeruginosa</i>	90	R	R	88	-	83	R	89	-	-	R	99	86	76	100	-	100	-	R	R	

NOTE: Third generation cephalosporins and piperacillin/tazobactam are unreliable for systemic infections with AmpC producing organisms (*E. cloacae*, *K. aerogenes*, or *C. freundii*), regardless of susceptibility data, due to the development of induced resistance on treatment.

Haemophilus influenzae beta lactamase positive: 20.9% (n=43)

Note: It is recommended that susceptibility data only be reported when there are at least 30 clinical isolates in the data set.

This antibiogram was created in compliance with CLSI M39-A4 Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, 4th Edition, January 2014.

2024

Cumulative Antimicrobial Susceptibility Report



INPATIENT DATA

PeaceHealth St. John Medical Center

January 1 – December 31, 2024

Dash (-) = not tested, inappropriate, or < 30 strains tested. R = intrinsically resistant.

GRAM POSITIVE ORGANISM	PERCENT SUSCEPTIBLE	# Isolates Tested	Beta lactams					Fluoro-quinolones		Amino-glycosides		Miscellaneous																									
			Penicillins/Cephalosporins									Ciprofloxacin		Levofloxacin		Gentamicin Synergy		Streptomycin Synergy		Clindamycin		Daptomycin		Erythromycin		Minocycline		Nitrofurantoin - urine only		Rifampin		Tetracycline		Trimethoprim/sulfamethoxazole		Vancomycin	
			Penicillin	Oxacillin	Ampicillin	Cefazolin	Ceftriaxone																														
<i>Enterococcus faecalis</i>	174	-	-	99	R	R	-	-	81	92	R	-	-	-	-	100	-	-	R	99																	
<i>Staphylococcus aureus</i> , MRSA	215	-	0	-	0	-	-	-	-	-	90	-	-	-	100	-	-	60	100	100																	
<i>Staphylococcus aureus</i> , MSSA	223	-	100	-	100	-	-	-	-	-	89	-	-	-	100	-	-	87	100	-																	
<i>Staphylococcus epidermidis</i>	31	-	32	-	32	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100									
<i>Streptococcus agalactiae</i> (Group B)	44	100	-	-	100	100	-	-	-	-	52	-	44	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100									
<i>Streptococcus anginosus</i>	41	100	-	-	-	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100									
<i>Streptococcus pneumoniae</i>	74	100*	-	-	-	100*	-	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-									
<i>Streptococcus pyogenes</i> (Group A)	73	100	-	-	100	100	-	-	-	-	72	-	72	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100									

*Non-meningitis breakpoint

Note: It is recommended that susceptibility data only be reported when there are at least 30 clinical isolates in the data set.

This antibiogram was created in compliance with CLSI M39-A4 Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, 4th Edition, January 2014.